<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lisa Pangemanan</style></author><author><style face="normal" font="default" size="100%">Irwanto</style></author><author><style face="normal" font="default" size="100%">Margarita M. Maramis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mozart K488 Addition Can Improve Depressive-Like Behavior in Rats: In Search of Better Management</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Corticosterone</style></keyword><keyword><style  face="normal" font="default" size="100%">Depressive-like behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine</style></keyword><keyword><style  face="normal" font="default" size="100%">Hippocampus</style></keyword><keyword><style  face="normal" font="default" size="100%">Melatonin</style></keyword><keyword><style  face="normal" font="default" size="100%">Mozart</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">348-354</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Fluoxetine is one of the medications used for the treatment of depression with several benefits, but some patients have a poor response to the drug. Several studies reported the use of Mozart music (K448) as an alternative therapy for treating the condition, yet the combination of Mozart and fluoxetine remains underexplored. In light of this, this study aims to assess the impact of combined fluoxetine and Mozart (K448) therapy on depressive-like behavior and associated hormonal changes in a rodent model subjected to Chronic Unpredictable Mild Stress (CUMS) conditions.&lt;strong&gt; Materials and Methods: &lt;/strong&gt;The depression-induced animal model received one of these three specified treatments: fluoxetine (F), Mozart (M), or a combination of fluoxetine and Mozart (F+M). The depressive-like behavior was assessed using a 24-hour sucrose preference test (SPT). Additionally, after 21 days of treatment, plasma corticosterone levels and hippocampal melatonin levels were assessed. Statistical analysis using either ANOVA or Kruskal-Wallis tests was then performed.&lt;strong&gt; Results: &lt;/strong&gt;The fluoxetine-Mozart group had higher SPT compared to CUMS group. However, they do not have a better result compared to other groups in terms of corticosterone and melatonin levels with values of respectively. &lt;strong&gt;Conclusion: &lt;/strong&gt;The combined therapy of fluoxetine and Mozart improved depressive-like behavior.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">348</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Lisa Pangemanan&lt;sup&gt;1*&lt;/sup&gt;, Irwanto&lt;sup&gt;2&lt;/sup&gt;, Margarita M. Maramis&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Psychiatry, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nandkishor Ramdas Kotagale</style></author><author><style face="normal" font="default" size="100%">Ankit Kedia</style></author><author><style face="normal" font="default" size="100%">Rupali Gite</style></author><author><style face="normal" font="default" size="100%">Shubham Nilkanth Rahmatkar</style></author><author><style face="normal" font="default" size="100%">Dinesh Yugraj Gawande</style></author><author><style face="normal" font="default" size="100%">Milind Janraoji Umekar</style></author><author><style face="normal" font="default" size="100%">Brijesh Gulabrao Taksande</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Withaferin A attenuates Alcohol Abstinence Signs in Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anxiety</style></keyword><keyword><style  face="normal" font="default" size="100%">Corticosterone</style></keyword><keyword><style  face="normal" font="default" size="100%">Ethanol withdrawal</style></keyword><keyword><style  face="normal" font="default" size="100%">HPA axis</style></keyword><keyword><style  face="normal" font="default" size="100%">Withaferin A.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2018</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">1190-1195</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; &lt;em&gt;Withania somnifera&lt;/em&gt; (WS) have been reported to inhibit acquisition and expression conditioned place preference, self-administration and withdrawal anxiety of psychostimulants. In the present work, we have assessed the effect of withaferin A on somatic and affective symptoms of ethanol withdrawal syndrome in rats. &lt;strong&gt;Methods:&lt;/strong&gt; Animals had given free access to ethanol uninterrupted for 21 days through liquid diet. Withaferin A (5, 10 and 20 mg/kg) was injected (ip) either during the development of ethanol dependence phase (days 15 &amp;ndash; 21 or 30 min before ethanol withdrawal assessment. Withdrawal signs characterized by changes in somatic signs were measured in the open field followed by evaluation of anxiety parameters, locomotion, and depressive behavior. &lt;strong&gt;Results:&lt;/strong&gt; Withaferin A treatment 30 min before 24 h postethanol withdrawal assessment did not alter the scores of somatic behavioral signs in ethanol abstinence animals. However, withaferin A (10 and 20 mg/kg, ip) from day 15-21 prevented the ethanol withdrawal-induced elevated scores of somatic behaviors, hyperlocomotion, depressive behavior, and anxiety. Withaferin A treatment did not influence the blood ethanol levels in dependent and withdrawn animals. However, withaferin A administration attenuated the elevated plasma corticosterone and ACTH levels in ethanol-withdrawn rats, suggesting withaferin A induced anti-stress effect and stabilization of HPA axis activity could have facilitated the inhibitory effect of withaferin A on ethanol withdrawal syndrome. &lt;strong&gt;Conclusion:&lt;/strong&gt; The finding supports further investigation of withaferin A and other bioactive components of WS in alcohol addiction.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1190</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Nandkishor Ramdas Kotagale, Ankit Kedia, Rupali Gite, Shubham Nilkanth Rahmatkar, Dinesh Yugraj Gawande, Milind Janraoji Umekar, Brijesh Gulabrao Taksande&lt;/strong&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: justify;&quot;&gt;Department of Pharmacology, Division of Neuroscience, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur (M.S.), INDIA.&lt;/p&gt;</style></auth-address></record></records></xml>